Good question.
There would be some logic to sooner than later right. They are attending OSA related cannabanoid conference in Q4. The DOD funded phase 2 SCI kicks off in Q4. Supposedly grant applications for KRM-ll-81 should be out there now and who knows if they get funding confirmation in Q4 or Q1 2025. And probably other updates on publications or NIH preclinicals, orphan collaborations, etc. Getting your corporation ducks in a row: funding, website, awareness, resources would be more beneficial ahead of all this.
But the OTC is not logical. Maybe trading crumbs on the EM has some value but to what end as time and possibly opportunity ticks on by?
Market Data 
Markets 
AI
